Axya Medical raises $6.8m for arthroscopic development
This article was originally published in Clinica
Beverly, Massachusetts-based Axya Medical has raised $6.8m from several venture capital firms led by The Vertical Group, of Summit, New Jersey. Axya president and CEO Paul Fenton said that the funds would be used to support expansion of sales and marketing, secure more distributors in the US and develop new products for the Axya Shoulder Fixation System used in arthroscopic shoulder procedures following sports or other injuries.
You may also be interested in...
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.